Celldex Therapeutics overview and recent stock context

Celldex Therapeutics (CLDX) has drawn investor attention after recent trading, with the stock closing at US$28.56. Short term moves included a 0.2% decline over the past day and a 5.2% pullback over the past week.

The recent pullback, including a 16% decline in the 1 month share price return, sits against a stronger backdrop, with a 1 year total shareholder return of 37.9% but weaker 3 and 5 year total shareholder returns.

If Celldex’s recent moves have you reassessing your watchlist, this is a good moment to scan other healthcare focused AI opportunities using the 39 healthcare AI stocks

With Celldex shares down over the past month but still higher over the past year, the stock trades at a large discount to both analyst targets and some intrinsic estimates. Is this a buying opportunity, or is future growth already priced in?

Preferred Price to Book multiple of 4.9x: Is it justified?

Celldex currently trades on a P/B of 4.9x, which sits against a last close of $28.56 and a SWS DCF fair value estimate of $84.52, so the picture is mixed.

P/B compares a company’s market value with its net assets. It is often used for early stage or unprofitable biopharma businesses where earnings and sales are still limited. For Celldex, meaningful revenue is small at $865K and the company reported a net loss of $283.646m, so the balance sheet and future potential are doing most of the heavy lifting in that 4.9x figure.

Against that, the stock is described as trading at a 66.2% discount to an intrinsic value estimate from the SWS DCF model, which projects future cash flows and discounts them back to today. However, the same set of checks also flags that Celldex is unprofitable, losses have been widening over 5 years, and the stock is considered expensive on P/B compared with both direct peers and the wider US Biotechs group.

The contrast is stark when you look at peers. Celldex’s 4.9x P/B is higher than the peer average of 3.8x and more than double the US Biotechs industry average of 2.3x. This indicates that the market is attaching a richer multiple to its equity than many comparables, even while the DCF view points to a large discount to intrinsic value.

Result: Price-to-book of 4.9x (OVERVALUED)

However, the story can change quickly if clinical trial setbacks emerge or if ongoing losses of US$283.646m limit flexibility to fund and advance the pipeline.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another view: DCF points in the opposite direction

The P/B comparison presents Celldex as expensive, yet the SWS DCF model indicates that the stock is trading at a large discount. The current $28.56 price sits 66.2% below an estimated fair value of $84.52. Which signal should carry more weight?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Celldex Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed signals on valuation and sentiment can be confusing, so act while the data is fresh and weigh the trade off between risks and rewards for yourself with the 2 key rewards and 3 important warning signs

Looking for more investment ideas?

If Celldex is already on your radar, do not stop there. Widen your search now and let fresh ideas challenge and refine your investment thinking.

• Target potential mispricings by scanning companies that combine solid fundamentals with attractive valuations using the 47 high quality undervalued stocks.
• Strengthen your income options by reviewing stocks that offer robust yield potential and consistency through the 10 dividend fortresses.
• Spot opportunities others may be overlooking by checking a focused list of fundamentally strong but less followed stocks in the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.